HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya.

AbstractBACKGROUND:
Artemether/lumefantrine (AL) has been adopted as the treatment of choice for uncomplicated malaria in Kenya and other countries in the region. Six-dose artemether/lumefantrine tablets are highly effective and safe for the treatment of infants and children weighing between five and 25 kg with uncomplicated Plasmodium falciparum malaria. However, oral paediatric formulations are urgently needed, as the tablets are difficult to administer to young children, who cannot swallow whole tablets or tolerate the bitter taste of the crushed tablets.
METHODS:
A randomized, controlled, open-label trial was conducted comparing day 28 PCR corrected cure-rates in 245 children aged 6-59 months, treated over three days with either six-dose of artemether/lumefantrine tablets (Coartem) or three-dose of artemether/lumefantrine suspension (Co-artesiane) for uncomplicated falciparum malaria in western Kenya. The children were followed-up with clinical, parasitological and haematological evaluations over 28 days.
RESULTS:
Ninety three percent (124/133) and 90% (121/134) children in the AL tablets and AL suspension arms respectively completed followed up. A per protocol analysis revealed a PCR-corrected parasitological cure rate of 96.0% at Day 28 in the AL tablets group and 93.4% in the AL suspension group, p = 0.40. Both drugs effectively cleared gametocytes and were well tolerated, with no difference in the overall incidence of adverse events.
CONCLUSION:
The once daily three-dose of artemether-lumefantrine suspension (Co-artesiane(R)) was not superior to six-dose artemether-lumefantrine tablets (Coartem) for the treatment of uncomplicated malaria in children below five years of age in western Kenya.
AuthorsElizabeth A Juma, Charles O Obonyo, Willis S Akhwale, Bernhards R Ogutu
JournalMalaria journal (Malar J) Vol. 7 Pg. 262 (Dec 22 2008) ISSN: 1475-2875 [Electronic] England
PMID19102746 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antimalarials
  • Artemether, Lumefantrine Drug Combination
  • Artemisinins
  • Drug Combinations
  • Ethanolamines
  • Fluorenes
  • Suspensions
  • Tablets
Topics
  • Analysis of Variance
  • Animals
  • Antimalarials (administration & dosage, adverse effects, therapeutic use)
  • Artemether, Lumefantrine Drug Combination
  • Artemisinins (administration & dosage, adverse effects, therapeutic use)
  • Child, Preschool
  • Drug Administration Schedule
  • Drug Combinations
  • Ethanolamines (administration & dosage, adverse effects, therapeutic use)
  • Fluorenes (administration & dosage, adverse effects, therapeutic use)
  • Follow-Up Studies
  • Humans
  • Infant
  • Kenya (epidemiology)
  • Malaria, Falciparum (drug therapy, epidemiology, parasitology)
  • Plasmodium falciparum (drug effects, isolation & purification)
  • Suspensions
  • Tablets
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: